ClinicalTrials.gg
Not yet recruitingNCT07174713ReNORMUpdated Jul 31, 2026

REverse LuNg Airway and Vascular RemOdeling in Asthma ReMission (ReNORM)

An interventional study of Biologic Therapy in Asthma; Eosinophilic, sponsored by Western University, Canada. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Western University, Canada · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

In this program of research, the investigators aim to answer the question: In patients with asthma aged 18-80, how do the lung airways and vessels respond to biologic therapy and what role does age and asthma duration have in this response? While about 4.6 million Canadians live with asthma, \~5-10% of patients have severe asthma meaning that multiple inhaled and systemic oral corticosteroid treatments have failed to improve symptoms and exacerbations, leading to lost work and school days and substantially diminished ability to participate in normal life. For such people, the vast majority of whom are middle aged and remember asthma as part of their entire lifespan, biologic immunomodulator therapies, which block the function of asthma inflammatory pathways, provide a final step-up therapy option. There is emerging evidence that prescribed in the right patient at the right time, the right biologic can result in clinical remission of asthma. While spontaneous clinical remission of asthma is rare, it has been documented in children in whom lung growth and remodeling is still possible. It remains unknown whether clinical remission in adults is accompanied by the reversal of pathologic remodeling, at the level of the airways and pulmonary vessels. This is critical to elucidate as investigators and physicians move forward with currently proposed criteria for "complete asthma remission". The inconvenient truth about asthma and age is that in older adult lungs, exposed to years of infection, exacerbations, smooth muscle remodeling and pulmonary vascular shunt, the mechanisms by which complete pathologic remission may be achieved are complex and poorly understood.

To address this knowledge gap, the investigators will evaluate 150 patients (Vancouver, Ottawa, Hamilton, London) (in three age tertiles 18-29; 30-59; 60-80) with severe asthma and 50 age- and sex matched healthy volunteers over 2-years using chest CT, MRI and pulmonary function tests. The investigators will use the pulmonary imaging measurements to generate an imaging-index of normal airway structure and function which will be compared with and significantly correlate with MR-guided bronchoscopic sample measurements made before and after 1-/2-years of treatment. The investigators will reveal the pathobiologic relationship between age, asthma duration, clinical remission and imaging normalization with direct comparison to histology-based airway measurements.

02

Conditions studied

  • Asthma; Eosinophilic

Browse trials for

Keywords

  • Hyperpolarized Xenon MRI
  • Clinical Remission
  • Biologic Therapy
  • Airway Remodeling
03

In context

Airway Remodeling

28 studies on the registry are indexed under Airway Remodeling; 5 are open to participants now.

This study's planned enrollment of 200 is above the median of 40 across 21 interventional studies indexed under Airway Remodeling.

Browse Airway Remodeling studies →

Lead sponsor

Western University, Canada is the lead sponsor of 224 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants eligible for inclusion in this study must meet all the following criteria:

  1. Participant understands study procedures and is willing to participate in the study as indicated by the patient's signature.
  2. Provision of written, prior to any study specific procedures.
  3. Males and females aged 18 to 80 years.
  4. Either diagnosed with severe asthma (GINA Step 5) and newly eligible for biologic therapy (based on ACQ-5, current treatment, exacerbation history, and blood eosinophils in accordance with approved criteria for omalizumab, mepolizumab, benralizumab, dupilumab, or tezepelumab), or a healthy volunteer with no history of chronic lung disease, matched by age and sex. Healthy participants must have a lifetime combustible tobacco and/or cannabis (including vaping) consumption of ≤5 pack-years.
  5. Women of (after menarche) must ensure that they are using an effective form of for at least 2 months prior to each imaging visit. Examples of effective birth control include:

    1. True sexual abstinence
    2. A vasectomized sexual partner
    3. Implanon®
    4. Female sterilization by tubal occlusion
    5. Effective intrauterine device (IUD)/levonogestrel intrauterine system (IUS)
    6. Depo-Provera™ injections
    7. Oral contraceptive
    8. Evra Patch™
    9. Nuvaring™
  6. Women of childbearing potential (after menarche) must agree to use a highly effective form of birth control, as defined above, from enrollment, throughout the study duration, and 8 weeks after last dose of study drug, with negative urine pregnancy test result at Visit 1-5.
  7. Male participants who are sexually active must agree to use a double barrier method of contraception (male condom with diaphragm or male condom with cervical cap) from the first dose of the study drug until 8 weeks after last dose

Exclusion criteria

Exclusion Criteria:

Participants fulfilling any of the following criteria are not eligible for inclusion in this study:

  1. Patient has an implanted mechanically, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants) (at the discretion of the MRI Technologist).
  2. In the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI or CT, such as severe claustrophobia.
  3. Participants who are pregnant, breastfeeding or have a positive pregnancy test at initial screening visit.
  4. Participant is unable to perform spirometry or plethysmography maneuvers.
  5. Participant is unable to perform MRI and CT breath-hold maneuvers.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Asthma - Biologic Therapy

    Participants with severe asthma (GINA 5) who are eligible to begin biologic therapy. Participants will undergo serial assessment with pulmonary imaging (CT, MRI), lung function testing, sputum collection, and symptom questionnaires. A subset of participants (\~15%) will be randomized to undergo MRI-guided bronchoscopy with airway sampling at baseline and 2 years.

    Biological: Biologic Therapy

  • No intervention
    Healthy Control

    Age- and sex-matched healthy participants with no history of lung disease. Participants will undergo pulmonary imaging (CT, MRI) and lung function testing at baseline and follow-up for comparison with the asthma group. No therapeutic intervention will be provided.

Interventions

  • BiologicalBiologic Therapy

    Participants with severe asthma (GINA 5) who are eligible to begin biologic therapy. Participants will undergo serial assessment with pulmonary imaging (CT, MRI), lung function testing, sputum collection, and symptom questionnaires. A subset of participants (\~15%) will be randomized to undergo MRI-guided bronchoscopy with airway sampling at baseline and 2 years.

06

What researchers measure

Primary outcomes

  1. Determine extent of imaging-based remission in patients with severe asthma following 1 and 2 years of biologic therapy

    Measured using 129Xe ventilation defect percent (VDP)

    Time frame: from baseline to year 1 and year 2

  2. Measure the extent and timing of clinical remission in patients with severe asthma as measured by changes in spirometry measurements of FEV1 and FVC

    Measured using forced expiratory volume in 1 second and forced vital capacity

    Time frame: from baseline to 1 year and 2 years

  3. To determine the extent and timing of clinical remission in patients with severe asthma using symptoms scores of ACQ-5 and ACT

    Measured using changes in asthma control questionnaire and asthma control test

    Time frame: From baseline to 1 year and 2 years

  4. Determine the extent and timing of imaging-based remission in patients with severe asthma using CT airway and vessel morphology

    Measured using computed tomography (CT) airway and vessel metrics

    Time frame: From baseline to 1 year and 2 years

  5. To determine the extent and timing of clinical remission using the clinical outcome of frequency of asthma exacerbations in patients with severe asthma

    Measured using the number of asthma exacerbations

    Time frame: from baseline to 1 year and 2 years

  6. To determine the extent and timing of clinical remission of patients with severe asthma using the clinical outcome of OCS use

    Measured by the frequency of oral corticosteroid usage

    Time frame: From baseline to 1 year and 2 years

  7. Determine the extent and timing of clinical remission in patients with severe asthma as measured by sputum and blood eosinophil counts

    Measured using blood and sputum eosinophil counts

    Time frame: From baseline to 1 year and 2 years

Secondary outcomes

  1. Timing and proportion of patients achieving clinical remission after biologic treatment as measured by FEV1 and FVC.

    Measured using forced expiratory volume at 1 second and forced vital capacity.

    Time frame: From baseline to 1 year and 2 years

  2. To determine the timing and proportion of patients achieving clinical remission as measured by ACQ-5 and ACT questionnaires.

    Measured by asthma control questionnaire and asthma control test questionnaire scores.

    Time frame: From baseline to 1 year and 2 years

  3. Determine the timing and proportion of patients with severe asthma achieving clinical remission after biologic treatment using FeNO.

    Measured using fractional exhaled nitric oxide (FeNO)

    Time frame: From baseline to 1 year and 2 years

  4. Determine the timing and proportion of patients with severe asthma achieving clinical remission using DLco.

    Measured using diffusing capacity of the lung for carbon monoxide (DLco)

    Time frame: From baseline to 1 year and 2 years

  5. Determine the timing and proportion of patients with severe asthma achieving clinical remission after biologic treatment using SGRQ score.

    Measured using St. George's Respiratory Questionnaire (SGRQ) score.

    Time frame: From baseline to 1 year and 2 years.

  6. Determine the timing and proportion of patients with severe asthma achieving clinical remission on biologic treatment using AQLQ scores.

    Measured using the Asthma Quality of Life Questionnaire (AQLQ) score.

    Time frame: From baseline to 1 year and 2 years

  7. Determine the timing and proportion of patients with severe asthma achieving imaging normalization after biologic treatment using 129-Xe MRI VDP

    Measured using the changes in 129-xenon MRI ventilation defect percent (VDP)

    Time frame: From baseline to 1 year and 2 years

  8. Determine the timing and proportion of patients with severe asthma achieving imaging normalization after biologic treatment using CT metrics

    Measured using computed tomography (CT) mucus-score, airway dimensions and vascular pruning

    Time frame: From baseline to 1 year and 2 years

  9. Determine the timing and proportion of patients with severe asthma achieving imaging normalization after biologic treatment using DLco.

    Measured using diffusing capacity of the lung for carbon monoxide (DLco)

    Time frame: From baseline to 1 year and 2 years

  10. Determine the timing and proportion of patients with severe asthma achieving imaging normalization after biologic treatment using RV/TLC

    Measured using the ratio of residual volume to total lung capacity (RV/TLC)

    Time frame: From baseline to 1 year and 2 years

  11. Determine the timing and proportion of patients with severe asthma achieving imaging normalization after biologic treatment using FRC.

    Measured using functional residual capacity (FRC).

    Time frame: From baseline to 1 year and 2 years

  12. Determine the relationships between clinical and imaging remission and generate predictive models for their achievement using changes in VDP

    Measured using ventilation defect percent (VDP)

    Time frame: from baseline to 12-weeks and 2-years

  13. Determine the relationship between clinical and imaging remission and generate predictive models for their achievement using changes in CT.

    Measured using computed tomography (CT) airway wall thickness, mucus metrics

    Time frame: From baseline to 12-weeks and 2-years

  14. Determine the relationships between clinical and imaging remission and generate predictive models for their achievement using FeNO.

    Measured using forced exhaled nitric oxide (FeNO).

    Time frame: From baseline to 12-weeks and 2-years

  15. Determine the relationships between clinical and imaging remission and generate predictive models for their achievement using ACQ-5 and ACT scores.

    Measured using asthma control questionnaire and asthma control test scores.

    Time frame: From baseline to 12-weeks and 2-years.

  16. Determine the relationships between clinical and imaging remission and generate predictive models for their achievement using sputum biomarkers.

    Measured using sputum eosinophil and cell count values

    Time frame: From baseline to 12-weeks and 2-years

  17. Determine the relationships between clinical and imaging remission and generate predictive models for their achievement using exacerbation history.

    Measured using patient's reported exacerbation history.

    Time frame: From baseline to 12-weeks and 2-years.

Other outcomes

  1. Quantify the relationships of imaging and pathologic markers of remodeling and develop a non-invasive imaging-index lung normalization.

    Measured using bronchoscopic airway histology (epithelial thickness, smooth muscle mass, vascularity).

    Time frame: From baseline (Day 0) to year 2

  2. Quantify the relationships of imaging and pathologic markers of remodeling and develop a non-invasive imaging-index lung normalization using MRI/CT correlations with histologic changes

    Measured using MRI, CT and histology values

    Time frame: From baseline to 2 years.

  3. Quantify the relationships of imaging and pathologic markers of remodeling and develop a non-invasive imaging-index lung normalization using MRI/CT fusion data

    Measured using MRI and CT measurements

    Time frame: From baseline to 2 years.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2030, 48 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2025
First posted
Sep 16, 2025
StartEst.
Oct 1, 2026
Primary completionEst.
Oct 2030
CompletionEst.
Oct 2030
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07174713
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Dr. Grace Parraga (Principal Investigator, Western University, Canada) — Principal investigator
First posted
Sep 16, 2025
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 2030 (estimated)
Completion
Oct 2030 (estimated)
Last update
Jul 31, 2026

Study contacts

Grace Parraga, PhD
Contact
gparraga@robarts.ca
519-931-5777 ext. 24197
Angela Wilson, RRT
Contact
awilson@robarts.ca
519-931-5777 ext. 24197
Grace Parraga, PhD
principal investigator · Robarts Research Institute, The University of Western Ontario

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion